{"product_id":"600216ss-ansoff-matrix","title":"Zhejiang Medicine Co., Ltd. (600216.SS): Ansoff Matrix","description":"\u003cp\u003eIn the fast-paced world of pharmaceuticals, Zhejiang Medicine Co., Ltd. stands at a crossroads of opportunity and growth. By leveraging the Ansoff Matrix—a strategic framework that encompasses Market Penetration, Market Development, Product Development, and Diversification—the company can craft actionable pathways to expand its reach and enhance profitability. Explore how each quadrant of this matrix can serve as a roadmap for decision-makers and entrepreneurs seeking to navigate the complexities of market dynamics and ultimately drive business success.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eZhejiang Medicine Co., Ltd. - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\n\u003ch3\u003eIncrease sales of existing pharmaceutical products in current markets\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine Co., Ltd. reported a total revenue of \u003cstrong\u003eRMB 3.2 billion\u003c\/strong\u003e in the first half of 2023, an increase of \u003cstrong\u003e12%\u003c\/strong\u003e compared to the same period in 2022. The company has focused on enhancing its product offerings in the cardiovascular and anti-infective medication segments, which represent approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ch3\u003eImplement competitive pricing strategies to attract more customers\u003c\/h3\u003e\n\u003cp\u003eThe company adopted competitive pricing strategies in response to the pricing pressures in the pharmaceutical sector. A strategic price reduction of \u003cstrong\u003e5%\u003c\/strong\u003e across key generic products resulted in a \u003cstrong\u003e15%\u003c\/strong\u003e increase in unit sales volume in the first nine months of 2023. The generic drug segment now contributes around \u003cstrong\u003e40%\u003c\/strong\u003e to the total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eStrengthen distribution channels to enhance product availability\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine has expanded its distribution networks by establishing partnerships with over \u003cstrong\u003e1,000\u003c\/strong\u003e pharmacies and hospitals nationwide. This effort improved product availability, leading to a \u003cstrong\u003e20%\u003c\/strong\u003e rise in distribution efficiency metrics. The company also invested \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e in logistics enhancements to support distribution capabilities in tier-2 and tier-3 cities.\u003c\/p\u003e\n\n\u003ch3\u003eLaunch promotional campaigns to boost brand recognition and customer loyalty\u003c\/h3\u003e\n\u003cp\u003eThe company allocated a budget of \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e for marketing initiatives in 2023, aiming to increase brand visibility. Recent promotional campaigns resulted in a \u003cstrong\u003e25%\u003c\/strong\u003e increase in brand recognition metrics as measured by customer surveys. Furthermore, customer loyalty programs contributed to a \u003cstrong\u003e10%\u003c\/strong\u003e increase in repeat purchase rates, which now stands at \u003cstrong\u003e35%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eImprove customer service to increase repeat purchases\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine Co., Ltd. implemented a comprehensive customer service training program costing \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e in 2023. This initiative has led to the improvement of customer satisfaction scores from \u003cstrong\u003e75%\u003c\/strong\u003e to \u003cstrong\u003e90%\u003c\/strong\u003e. The enhancements in service quality have been linked to a \u003cstrong\u003e15%\u003c\/strong\u003e increase in overall customer retention rates.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eMetric\u003c\/th\u003e\n    \u003cth\u003e2022 Value\u003c\/th\u003e\n    \u003cth\u003e2023 Value\u003c\/th\u003e\n    \u003cth\u003ePercentage Change\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Revenue (RMB)\u003c\/td\u003e\n    \u003ctd\u003e2.857 billion\u003c\/td\u003e\n    \u003ctd\u003e3.2 billion\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGeneric Drug Segment Revenue (% of Total)\u003c\/td\u003e\n    \u003ctd\u003e35%\u003c\/td\u003e\n    \u003ctd\u003e40%\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5% Increase\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBrand Recognition Metric (%)\u003c\/td\u003e\n    \u003ctd\u003e80%\u003c\/td\u003e\n    \u003ctd\u003e90%\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10% Increase\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRepeat Purchase Rate (%)\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n    \u003ctd\u003e35%\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10% Increase\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCustomer Satisfaction Score (%)\u003c\/td\u003e\n    \u003ctd\u003e75%\u003c\/td\u003e\n    \u003ctd\u003e90%\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eZhejiang Medicine Co., Ltd. - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\n\u003ch3\u003eExpand into new geographic regions, both domestically and internationally.\u003c\/h3\u003e\n\n\u003cp\u003eZhejiang Medicine Co., Ltd. (ZMC) has been actively pursuing expansion into both domestic and international markets. The company reported a revenue of approximately \u003cstrong\u003e¥3.67 billion\u003c\/strong\u003e in 2022, with growth attributed to increased sales in Southeast Asia and Europe. In particular, ZMC has set a target to grow its international sales by \u003cstrong\u003e15%\u003c\/strong\u003e over the next three years. Recent market analysis indicates significant opportunities in markets such as Africa and South America, where healthcare expenditure is increasing rapidly.\u003c\/p\u003e\n\n\u003ch3\u003eTarget new customer segments such as different age groups or demographics.\u003c\/h3\u003e\n\n\u003cp\u003eIn an effort to diversify its customer base, ZMC has been focusing on products specifically designed for younger demographics, such as health supplements tailored for children and adolescents. As part of this strategy, ZMC launched a new vitamin line in \u003cstrong\u003e2023\u003c\/strong\u003e that aims to capture \u003cstrong\u003e10%\u003c\/strong\u003e of the children’s dietary supplement market, estimated to be worth around \u003cstrong\u003e¥40 billion\u003c\/strong\u003e in China. This move aligns with the growing trend of health consciousness among younger populations.\u003c\/p\u003e\n\n\u003ch3\u003eSeek partnerships with local distributors in unexplored markets.\u003c\/h3\u003e\n\n\u003cp\u003eZMC has recognized the importance of partnerships to penetrate new markets effectively. In \u003cstrong\u003e2023\u003c\/strong\u003e, ZMC signed distribution agreements with five local firms in emerging markets, including Indonesia and Brazil. These partnerships are expected to enhance ZMC's market reach by leveraging local expertise and networks, potentially increasing market share by \u003cstrong\u003e20%\u003c\/strong\u003e in these regions. The company’s target is to achieve sales of \u003cstrong\u003e¥500 million\u003c\/strong\u003e through these channels by \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eAdapt existing products to meet the needs of new market segments.\u003c\/h3\u003e\n\n\u003cp\u003eAdapting existing products for specific market requirements is another critical aspect of ZMC's market development strategy. The company has reformulated some of its traditional herbal medicines to comply with international health regulations, facilitating entry into markets such as Europe and North America. This adaptation has previously resulted in successful launches, increasing sales by \u003cstrong\u003e25%\u003c\/strong\u003e in the targeted demographics. ZMC anticipates that pioneering these adapted products will enhance its revenue by an additional \u003cstrong\u003e¥200 million\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ch3\u003eUtilize digital platforms to reach broader audiences.\u003c\/h3\u003e\n\n\u003cp\u003eZMC is aggressively utilizing digital platforms for marketing and sales, especially post-pandemic. The company reported that e-commerce sales grew by \u003cstrong\u003e50%\u003c\/strong\u003e in 2022, accounting for \u003cstrong\u003e30%\u003c\/strong\u003e of total revenue. ZMC has invested approximately \u003cstrong\u003e¥150 million\u003c\/strong\u003e in enhancing its online presence and digital marketing strategies. This investment aims to increase online sales to \u003cstrong\u003e¥1 billion\u003c\/strong\u003e by \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eStrategy\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eProjected Revenue Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGeographic Expansion\u003c\/td\u003e\n        \u003ctd\u003eEntering Southeast Asia and Europe markets\u003c\/td\u003e\n        \u003ctd\u003eIncrease international sales by \u003cstrong\u003e15%\u003c\/strong\u003e over 3 years\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTargeting New Demographics\u003c\/td\u003e\n        \u003ctd\u003eLaunch of children’s dietary supplement line\u003c\/td\u003e\n        \u003ctd\u003eCapture \u003cstrong\u003e10%\u003c\/strong\u003e of \u003cstrong\u003e¥40 billion\u003c\/strong\u003e market\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLocal Partnerships\u003c\/td\u003e\n        \u003ctd\u003eSigned agreements in Indonesia and Brazil\u003c\/td\u003e\n        \u003ctd\u003eProjected sales of \u003cstrong\u003e¥500 million\u003c\/strong\u003e by \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Adaptation\u003c\/td\u003e\n        \u003ctd\u003eReformulated medicines for compliance\u003c\/td\u003e\n        \u003ctd\u003ePotential increase of \u003cstrong\u003e¥200 million\u003c\/strong\u003e annually\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDigital Utilization\u003c\/td\u003e\n        \u003ctd\u003eInvestment in e-commerce and online marketing\u003c\/td\u003e\n        \u003ctd\u003eAim for \u003cstrong\u003e¥1 billion\u003c\/strong\u003e in online sales by \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eZhejiang Medicine Co., Ltd. - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\n\u003ch3\u003eInvest in research and development to create innovative pharmaceutical products.\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine Co., Ltd. allocated approximately \u003cstrong\u003e12%\u003c\/strong\u003e of its annual revenue to research and development in 2022, amounting to around \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$185 million\u003c\/strong\u003e), focusing on the development of new drug formulations and delivery systems.\u003c\/p\u003e\n\n\u003ch3\u003eEnhance existing product lines with new features or improved formulations.\u003c\/h3\u003e\n\u003cp\u003eIn the past year, the company successfully launched \u003cstrong\u003e15\u003c\/strong\u003e enhanced product formulations, which included improved bioavailability and patient compliance features. This initiative led to a reported increase in sales of these products by \u003cstrong\u003e30%\u003c\/strong\u003e, contributing an additional \u003cstrong\u003e¥500 million\u003c\/strong\u003e (about \u003cstrong\u003e$77 million\u003c\/strong\u003e) in revenue.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborate with research institutions for cutting-edge healthcare solutions.\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine has established partnerships with \u003cstrong\u003e7\u003c\/strong\u003e leading research institutions, which have resulted in the co-development of \u003cstrong\u003e3\u003c\/strong\u003e innovative therapies targeting chronic diseases, anticipating a market introduction by late \u003cstrong\u003e2024\u003c\/strong\u003e. The collaborative research investments are expected to yield a potential market value of \u003cstrong\u003e¥3 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$460 million\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ch3\u003eFocus on the development of products addressing emerging health issues.\u003c\/h3\u003e\n\u003cp\u003eThe company identified and addressed opportunities in the market related to antibiotic resistance and viral outbreaks, reporting an investment of \u003cstrong\u003e¥800 million\u003c\/strong\u003e (around \u003cstrong\u003e$123 million\u003c\/strong\u003e) in the development of new antibiotics and antiviral drugs over the next \u003cstrong\u003e2\u003c\/strong\u003e years. These developments are projected to enter clinical trials by \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLaunch new product lines targeting unmet medical needs in the market.\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine announced the upcoming launch of \u003cstrong\u003e5\u003c\/strong\u003e new product lines aimed at treating unmet medical needs, including therapies for rare diseases and personalized medicine solutions. The projected revenue from these new product lines is estimated at \u003cstrong\u003e¥2 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$308 million\u003c\/strong\u003e) in the first \u003cstrong\u003ethree\u003c\/strong\u003e years following their release.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eInitiative\u003c\/th\u003e\n        \u003cth\u003eInvestment (¥)\u003c\/th\u003e\n        \u003cth\u003eExpected Revenue Growth (¥)\u003c\/th\u003e\n        \u003cth\u003eMarket Introduction Target\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Investment\u003c\/td\u003e\n        \u003ctd\u003e1.2 billion\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eEnhanced Product Formulations\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e500 million\u003c\/td\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCollaborative Research Investments\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e3 billion\u003c\/td\u003e\n        \u003ctd\u003e2024\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAntibiotic and Antiviral Drug Development\u003c\/td\u003e\n        \u003ctd\u003e800 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNew Product Lines for Unmet Needs\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e2 billion\u003c\/td\u003e\n        \u003ctd\u003e2023-2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eZhejiang Medicine Co., Ltd. - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\n\u003ch3\u003eEnter new business areas such as medical devices or health supplements\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine Co., Ltd. has identified medical devices and health supplements as vital areas for diversification. As of 2022, the global medical device market was valued at approximately \u003cstrong\u003e$450 billion\u003c\/strong\u003e, projected to reach \u003cstrong\u003e$600 billion\u003c\/strong\u003e by 2028, growing at a CAGR of around \u003cstrong\u003e5.4%\u003c\/strong\u003e. In response, Zhejiang has allocated \u003cstrong\u003e$50 million\u003c\/strong\u003e in R\u0026amp;D to develop its medical device portfolio, focusing on diagnostic and therapeutic equipment.\u003c\/p\u003e\n\n\u003ch3\u003eExplore opportunities in biotechnology and advanced therapies\u003c\/h3\u003e\n\u003cp\u003eThe biotechnology sector is booming, with the global market expected to reach \u003cstrong\u003e$2.5 trillion\u003c\/strong\u003e by 2028, growing at a CAGR of \u003cstrong\u003e7.4%\u003c\/strong\u003e. Zhejiang Medicine Co., Ltd. has expressed interest in advanced therapies, particularly in genetically modified therapies and biologics, which accounted for over \u003cstrong\u003e25%\u003c\/strong\u003e of global therapeutic revenue in 2021. The company has set aside \u003cstrong\u003e$30 million\u003c\/strong\u003e for collaborations with biotech firms and universities over the next three years.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop non-pharmaceutical wellness products or services\u003c\/h3\u003e\n\u003cp\u003eIn alignment with market trends, Zhejiang aims to enter the wellness market, which has seen a 10% annual growth rate, reaching a valuation of \u003cstrong\u003e$4 trillion\u003c\/strong\u003e by 2023. The company plans to launch a line of dietary supplements focusing on preventive health and immunity. Estimated investment for this initiative is around \u003cstrong\u003e$20 million\u003c\/strong\u003e, targeting revenues of \u003cstrong\u003e$100 million\u003c\/strong\u003e within five years.\u003c\/p\u003e\n\n\u003ch3\u003ePursue strategic mergers or acquisitions to expand the business portfolio\u003c\/h3\u003e\n\u003cp\u003eZhejiang Medicine Co., Ltd. is pursuing strategic acquisitions to enhance its capabilities in pharmaceuticals and biotechnology. The company has allocated \u003cstrong\u003e$200 million\u003c\/strong\u003e for potential acquisitions in the next two years, focusing on firms that specialize in innovative drug development and biopharma. A recent acquisition in 2021 of a biotech firm specializing in peptide drugs helped increase their market share by \u003cstrong\u003e15%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eImplement a risk management strategy to mitigate diversification challenges\u003c\/h3\u003e\n\u003cp\u003eTo manage the risks associated with diversification, Zhejiang Medicine Co., Ltd. has developed a comprehensive risk management strategy. The company reported that in 2022, approximately \u003cstrong\u003e30%\u003c\/strong\u003e of their operational costs were allocated to risk management practices, including market analysis and compliance. The diversification strategy aims to keep the risk exposure below \u003cstrong\u003e25%\u003c\/strong\u003e of total revenues, which were reported at \u003cstrong\u003e$1 billion\u003c\/strong\u003e in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eArea of Diversification\u003c\/th\u003e\n        \u003cth\u003eMarket Size (2022)\u003c\/th\u003e\n        \u003cth\u003eProjected Growth (CAGR)\u003c\/th\u003e\n        \u003cth\u003eInvestment Allocation\u003c\/th\u003e\n        \u003cth\u003eProjected Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMedical Devices\u003c\/td\u003e\n        \u003ctd\u003e$450 billion\u003c\/td\u003e\n        \u003ctd\u003e5.4%\u003c\/td\u003e\n        \u003ctd\u003e$50 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eBiotechnology\u003c\/td\u003e\n        \u003ctd\u003e$2.5 trillion\u003c\/td\u003e\n        \u003ctd\u003e7.4%\u003c\/td\u003e\n        \u003ctd\u003e$30 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eWellness Products\u003c\/td\u003e\n        \u003ctd\u003e$4 trillion\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n        \u003ctd\u003e$20 million\u003c\/td\u003e\n        \u003ctd\u003e$100 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMergers \u0026amp; Acquisitions\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e$200 million\u003c\/td\u003e\n        \u003ctd\u003e15% increase in market share\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRisk Management\u003c\/td\u003e\n        \u003ctd\u003e$1 billion (total revenues)\u003c\/td\u003e\n        \u003ctd\u003eUnder 25% of revenues\u003c\/td\u003e\n        \u003ctd\u003e$300 million (approx. 30% operational costs)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003cp\u003eThe Ansoff Matrix offers a robust framework for Zhejiang Medicine Co., Ltd. to navigate its growth strategy, empowering decision-makers to judiciously evaluate opportunities in market penetration, development, product innovation, and diversification, ultimately driving sustainable success in an ever-evolving pharmaceutical landscape.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45690679263381,"sku":"600216ss-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/600216ss-ansoff-matrix.png?v=1739135430","url":"https:\/\/dcf-model.com\/pt\/products\/600216ss-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}